Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Slavin, S.
Right arrow Articles by Nagler, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slavin, S.
Right arrow Articles by Nagler, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 9:S31-S39, 1998
© 1998 European Society for Medical Oncology

Reviews

Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma

S. Slavin and A. Nagler

Department of Bone Marrow Transplantation, Cancer Immunotherapy & Immunobiology Research Center, Hadassah University Hospital Jerusalem, Israel

Correspondence to: Dr. S. Slavin, Department of Bone Marrow Transplantation, Cancer Immunotherapy & Immunobiology Research Center, Hadassah University Hospital, Jerusalem 91120, Israel E-mail: slavin{at}hadassah.org.il

Relapse is the major obstacle for successful transplantations in lymphoma. One of the ways to reduce relapse rates is to intensify immune-mediated effector mechanisms. Graft-versus-lymphoma may be achieved either by administration of cytokines or by allogeneic cell-mediatedadoptive immunotherapy. The use of allogeneic non-myeloablative stem cell transplantation (SCT) isanother option which may be applicable to all age groups. It remains to be seen whether non-myeloablative SCT will result in a lesser degree of relapse and higher disease-free survival in lymphomapatients.

graft-versus- lymphoma, immunotherapy, inter-feron-{alpha}, interleukin-2, minimal residual disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
F. Jundt, N. Raetzel, C. Muller, C. F. Calkhoven, K. Kley, S. Mathas, A. Lietz, A. Leutz, and B. Dorken
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas
Blood, September 1, 2005; 106(5): 1801 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. J. Savage, S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. de Leval, P. Kurtin, P. D. Cin, C. Ladd, F. Feuerhake, et al.
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
Blood, December 1, 2003; 102(12): 3871 - 3879.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Boudova, E. Torlakovic, J. Delabie, P. Reimer, B. Pfistner, S. Wiedenmann, V. Diehl, H.-K. Muller-Hermelink, and T. Rudiger
Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma
Blood, November 15, 2003; 102(10): 3753 - 3758.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood, July 30, 2002; 100(4): 1141 - 1152.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.